Prostaglandins

Prostaglandins

 

 

Bimatoprost,155206-00-1
Bimatoprost
Bimatoprost,155206-00-1
CAS
155206-00-1
Molecular Formula
C25H37NO4 
Molecular Weight
415.57
Systematic Name
Lumigan; AGN 192024
Assay
98.0%
Certificate of analysis
Bimatoprost,155206-00-1
View via PDF file
Bimatoprost,155206-00-1
Specification
Appearance
White or almost white powder
Complies
Identification
(1) by HPLC
Complies
(2) by IR
Complies
Optical rotation
+33.0º to +37.0 º
35.4 º
Water
Not more 1.0%
0.38%
Residual substance
15R-Bimatoprost: N.M.T:0.3%
0
Bimatoprost free acid: N.M.T:0.1%
0
5,6-trans-bimatoprost: N.M.T:0.5%
0
Any single impurity: N.M.T:0.1%
0.06%
Total impurities: N.M.T:0.5%
0.06%
Residual solvents
Acetonitrile: N.M.T:0.04%
0
Ethanol: N.M.T:0.5%
0
n-Hexane: N.M.T:0.05%
0
Ethyl acetate: N.M.T:0.4%
0.02%
Assay
96.0% to 102.0%
99.5%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Related Prostagandins
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(Bimatoprost,155206-00-1).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.